Brean Murray Carret & Co. Starts Optimer Pharmaceuticals (OPTR) at Buy; Dificid Launch Going Well
Tweet Send to a Friend
Brean Murray Carret & Co. initiates coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Buy. PT $20.00.
Brean analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Brean analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
